PJ, October 2023, Vol 311, No 7978

How the RPS has supported the advancement of pharmacist prescribing

Laura Wilson, director for Scotland at the Royal Pharmaceutical Society, recounts how the Society lobbied for wider use of pharmacist independent prescribers.…

Burnout among pharmacy professionals needs to be addressed at ‘systemic level’, RPS report finds

The report stated that individuals should seek to prioritise their wellbeing, but highlighted that many factors affecting staff wellbeing have been created by the healthcare system.…

An audit of pharmacological therapy on discharge for patients admitted with acute decompensated HFrEF

Pharmacological management of acute decompensated heart failure with reduced ejection fraction (HFrEF) reduces mortality and morbidity[1]. International and local guidelines recommend with class I evidence for the use of renin-angiotensin system inhibitor (RAASi), beta-blocker, miner…

Community pharmacy independent prescribing sites expected to be established by November 2023

Exclusive: NHS England said integrated care boards are currently working towards establishing pathfinder sites and governance arrangements for the Independent Prescribing Pathfinder Programme.…

Colchicine for cardiovascular disease: is UK clinical practice missing out?

A deep dive into whether colchicine, an ancient treatment for inflammation, has a future in cardiovascular disease therapy in the UK.…

Esketamine outperforms quetiapine for treatment-resistant depression, study finds

Patients with treatment-resistant depression, who received esketamine nasal spray plus an antidepressant, were more likely to achieve remission at eight weeks than those who received quetiapine and an antidepressant, according to trial results.…

BTK inhibitors: what pharmacists need to know

In this episode of The PJ Pod, we consider the impact bruton tyrosine kinase (BTK) inhibitors have had on care for patients with B-cell malignancies and explore how pharmacists can help patients get the best out of their treatment regimens.…

Supported content

‘Game changing’ cancer drug to be withdrawn by manufacturer

Takeda — manufacturer of Exkivity (mobocertinib), which is used to treat a rare form of lung cancer — has announced it intends to withdraw the drug after it did not meet its primary endpoint in a phase III trial.…

First pharmacists credentialed as advanced practitioners under new e-portfolio system

Seven pharmacists have been credentialed as advanced practitioners after demonstrating advanced capabilities.…

Nina Barnett (1965–2023)

“Inspirational” pharmacy stalwart Nina Barnett will leave behind a legacy that her peers say they will proudly continue to take forward.…